Leveraging single-cell level multiplexed immunofluorescence (IF)

To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. Sorry for the convenience.

Date

November 10, 2020

Characterizing the tumor microenvironment after IO biomarker targeting in clinical trials

What will be discussed?

Gain insight as to how Multiplexed Immunofluorescence can be Utilized to Provide a Complete View of Tumor Behavior
Track the Benefits of High-Order Multiplex Panels for Exploration of Immune Evasion Mechanisms
Preview an Example of how MultiOmyx Analysis was Used to Characterize the Biological Effects of Dual PD-1 and CXCR4 Targeting in a Clinical Trial